Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n
Action and use<\/strong><\/p>\n Dopamine receptor antagonist; neuroleptic.<\/p>\n Preparation <\/strong><\/p>\n Sulpiride Tablets<\/p>\n N-[[(2RS)-1-Ethylpyrrolidin-2-yl)]methyl]-2-methoxy-5-sulfamoylbenzamide.<\/p>\n Content<\/p>\n 98.5 per cent to 101.0 per cent (dried substance).<\/p>\n White or almost white, crystalline powder.<\/p>\n Practically insoluble in water, sparingly soluble in methanol, slightly soluble in ethanol (96 per cent) and in methylene chloride. It dissolves in dilute solutions of mineral acids and alkali hydroxides.<\/p>\n First identification: B.<\/em><\/p>\n Second identification: A, C, D.<\/em><\/p>\n A. Melting point (2.2.14): 177 \u00b0C to 181 \u00b0C.<\/p>\n B. Infrared absorption spectrophotometry (2.2.24).<\/p>\n Comparison\u00a0 sulpiride CRS.<\/p>\n C. Examine the chromatograms obtained in the test for impurity A.<\/p>\n Detection\u00a0 Examine in ultraviolet light at 254 nm.<\/p>\n Results The principal spot in the chromatogram obtained with test solution (b) is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).<\/p>\n D. To about 1 mg in a porcelain dish, add 0.5 mL of sulfuric acid R and 0.05 mL of formaldehyde solution R. Examined in ultraviolet light at 365 nm, the solution shows blue fluorescence.<\/p>\n The solution is clear (2.2.1) and not more intensely coloured than reference solution Y6 (2.2.2, Method I). Dissolve 1.0 g in dilute acetic acid R and dilute to 10 mL with the same acid.<\/p>\n Impurity A. Thin-layer chromatography (2.2.27)<\/p>\n Test solution (a) Dissolve 0.20 g of the substance to be examined in methanol R, sonicate until dissolution is complete and dilute to 10.0 mL with the same solvent.<\/p>\n Test solution (b)\u00a0 Dilute 1.0 mL of test solution (a) to 10.0 mL with methanol R.<\/p>\n Reference solution (a)\u00a0 Dissolve 20 mg of sulpiride CRS in methanol R and dilute to 10.0 mL with the same solvent.<\/p>\n Reference solution (b) Dissolve 5.0 mg of sulpiride impurity A CRS in methanol R and dilute to 25.0 mL with the same solvent. Dilute 1.0 mL of the solution to 10.0 mL with methanol R.<\/p>\n Plate\u00a0 TLC silica gel F254 plate R.<\/p>\n Mobile phase concentrated ammonia R, dioxan R, methanol R, methylene chloride R (2:10:14:90 V\/V\/V\/V). Application 10 \u00b5L.<\/p>\n Development\u00a0 Over 1\/2 of the plate.<\/p>\n Drying\u00a0 In air.<\/p>\n Detection Examine in ultraviolet light at 254 nm for identification test C and then spray with ninhydrin solution R; heat at 100-105 \u00b0C for 15 min and examine in daylight.<\/p>\n Limit\u00a0 Test solution (a):<\/p>\n \u2014 impurity A: any spot due to impurity A is not more intense than the corresponding spot in the chromatogram obtained with reference solution (b) (0.1 per cent).<\/p>\n Liquid chromatography (2.2.29).<\/p>\n Test solution Dissolve 0.100 g of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.<\/p>\n Reference solution (a) Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.<\/p>\n Reference solution (b) Dissolve 5 mg of the substance to be examined and 5 mg of sulpiride impurity B CRS in the mobile phase and dilute to 50.0 mL with the mobile phase.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n \u2014 stationary phase: end-capped octylsilyl silica gel for chromatography R (5 \u00b5m).<\/p>\n Mobile phase\u00a0 Mix 10 volumes of acetonitrile R, 10 volumes of methanol R and 80 volumes of a solution containing 6.8 g\/L of potassium dihydrogen phosphate R and 1 g\/L of sodium octanesulfonate R, previously adjusted to pH 3.3 with phosphoric acid R.<\/p>\n Flow rate\u00a0 1.5 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 240 nm.<\/p>\n Injection\u00a0 10 \u00b5L.<\/p>\n Run time\u00a0 Twice the retention time of sulpiride.<\/p>\n Identification of impurities Use the chromatogram obtained with reference solution (b) to identify the peak due to impurity B.<\/p>\n Relative retention\u00a0 With reference to sulpiride (retention time = about 15 min): impurity B = about 0.7.<\/p>\n System suitability\u00a0 Reference solution (b):<\/p>\n \u2014 resolution: minimum 2.5 between the peaks due to impurity B and sulpiride.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 for each impurity, use the concentration of sulpiride in reference solution (a).<\/p>\n Limits:<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 0.3 per cent;<\/p>\n \u2014 reporting threshold: 0.05 per cent.<\/p>\n Chlorides (2.4.4)<\/strong><\/p>\n Maximum 100 ppm.<\/p>\n Shake 1.0 g with 20 mL of water R. Filter through a sintered-glass filter (40) (2.1.2). To 10 mL of the filtrate add 5 mL of water R.<\/p>\n Iron (2.4.9)<\/strong><\/p>\n Maximum 10 ppm.<\/p>\n Ignite 1.0 g in a silica crucible. To the residue add 1 mL of 1 M hydrochloric acid, 3 mL of water R and 0.1 mL of nitric acid R. Heat on a water-bath for about 5 min.<\/p>\n Place the solution in a test-tube. Rinse the crucible with 4 mL of water R. Collect the rinsings in the test-tube and dilute to 10 mL with water R.<\/p>\n Loss on drying (2.2.32)<\/strong><\/p>\n Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n Sulfated ash (2.4.14)<\/strong><\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n Dissolve 0.250 g in 80 mL of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n 1 mL of 0.1 M perchloric acid is equivalent to 34.14 mg of C15<\/sub>H23<\/sub>N3<\/sub>O4<\/sub>S.<\/p>\n Specified impurities\u00a0 A.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D, E, F, G.<\/em><\/p>\n A. [(2RS)-1-ethylpyrrolidin-2-yl]methanamine,<\/p>\n B. methyl 2-methoxy-5-sulfamoylbenzoate,<\/p>\n C. ethyl 2-methoxy-5-sulfamoylbenzoate,<\/p>\n D. 2-methoxy-5-sulfamoylbenzoic acid,<\/p>\n E. 2-methoxy-5-sulfamoylbenzamide,<\/p>\n F. N-[[(2RS)-1-ethyl-1-oxidopyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide,<\/p>\n G. N-[[(2RS)-1-\u00e9thylpyrrolidin-2-yl]m\u00e9thyl]-2-hydroxy-5-sulfamoylbenzamide.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Dopamine receptor antagonist; neuroleptic. Preparation Sulpiride Tablets DEFINITION N-[[(2RS)-1-Ethylpyrrolidin-2-yl)]methyl]-2-methoxy-5-sulfamoylbenzamide. Content 98.5 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Practically insoluble in water, sparingly soluble in methanol, slightly soluble in ethanol (96 per cent) and in…<\/p>\n","protected":false},"author":5,"featured_media":31767,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-31763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=31763"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31763\/revisions"}],"predecessor-version":[{"id":31777,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31763\/revisions\/31777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/31767"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=31763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=31763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=31763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Solubility<\/h3>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h1>\n
Appearance of solution<\/h3>\n
Related substances<\/h3>\n
ASSAY<\/h2>\n
IMPURITIES<\/h2>\n